SNI-2011 TO TREAT PATIENTS WITH SJOGREN'S SYNDROME

SNI-2011 治疗干燥综合征患者

• 批准号: 6281714
• 负责人: ALAN W FRIEDMAN
• 金额: $ 1.36万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6281714
• 关键词: Sjogren's syndrome; cholinergic agents; clinical research; human subject; human therapy evaluation; immunopathology chemotherapy

Sjogren's syndrome is an immunological disorder characterized by dry eyes and dry mouth, which includes diminished or absent secretion of glandular tissue. SNI-2011, a quinuclidine derivative of acetylcholine, is a muscarinic agonist associated with improved glandular ability to increase salivation and lacrimation. This study will compare the efficacy of two doses of SNI-2011 (15 mg and 30 mg tid) with placebo on the patients' subjective global evaluation of dryness (mouth, eyes, and overall).

干燥综合征是一种免疫性疾病， 和口干，包括腺体分泌减少或缺乏 组织. SNI-2011是乙酰胆碱的奎宁环衍生物， 与改善的腺体增加的能力相关的毒蕈碱激动剂 流涎和流泪。 这项研究将比较两种药物的疗效。 SNI-2011（15 mg和30 mg tid）与安慰剂联合给药， 干燥的主观总体评价（口腔、眼睛和整体）。